U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula Ca.HO4P
Molecular Weight 136.057
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANHYDROUS DIBASIC CALCIUM PHOSPHATE

SMILES

[Ca++].OP([O-])([O-])=O

InChI

InChIKey=FUFJGUQYACFECW-UHFFFAOYSA-L
InChI=1S/Ca.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+2;/p-2

HIDE SMILES / InChI

Molecular Formula Ca
Molecular Weight 40.078
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO4P
Molecular Weight 95.9793
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred
PubMed

PubMed

TitleDatePubMed
Transient kinetic analysis of the 130-kDa myosin I (MYR-1 gene product) from rat liver. A myosin I designed for maintenance of tension?
1999 Jul 30
Characterization of the human cysteinyl leukotriene CysLT1 receptor.
1999 Jun 24
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.
1999 Sep
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity.
1999 Sep 20
Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells.
2000 Aug
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors.
2000 Feb 15
alpha(1E) subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties.
2000 Jan 1
Vanadate induces calcium signaling, Ca2+ release-activated Ca2+ channel activation, and gene expression in T lymphocytes and RBL-2H3 mast cells via thiol oxidation.
2000 Jan 15
Polyoxygenated dysidea sterols that inhibit the binding of [I125] IL-8 to the human recombinant IL-8 receptor type A.
2000 May
Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors.
2000 Nov
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.
2000 Nov 10
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement.
2000 Oct 15
Chemokines induce eosinophil degranulation through CCR-3.
2000 Sep
Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake.
2000 Sep
Ca2+-induced contraction of cat esophageal circular smooth muscle cells.
2001 Apr
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells.
2001 Aug
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds.
2001 Dec 21
Molecular and functional characterization of a family of rat brain T-type calcium channels.
2001 Feb 9
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.
2001 Feb 9
Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine.
2001 Jul
Analysis of the native quaternary structure of vanilloid receptor 1.
2001 Jul 27
Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B.
2001 Jun
Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D.
2001 Jun
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.
2001 Jun 8
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes.
2001 Mar 2
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis.
2001 Nov 30
Familial intrahepatic cholestasis 1: studies of localization and function.
2001 Oct
Microarray analysis of differential gene expression in lead-exposed astrocytes.
2001 Oct 1
Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels.
2001 Oct 12
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.
2001 Oct 26
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.
2001 Sep
Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore.
2001 Sep 1
Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze.
2001 Sep 7
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells.
2002 Apr 19
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells.
2002 Dec
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells.
2002 Feb
Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
2002 Jan 15
Expression of functional CCR and CXCR chemokine receptors in podocytes.
2002 Jun 15
Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor.
2002 Mar
Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart.
2002 Mar
Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice.
2002 Mar 15
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products.
2002 May 15
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit.
2002 Sep
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death.
2002 Sep 6
A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs.
2002 Sep 6
[Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate].
2006 Oct
Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity.
2009 Jul-Aug
Effect of calcium phosphate and vitamin D₃ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron.
2014 Jan 17
Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review.
2014 Jul
Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
2015 Sep 16
Patents

Sample Use Guides

Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:59:40 GMT 2025
Edited
by admin
on Mon Mar 31 17:59:40 GMT 2025
Record UNII
L11K75P92J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
II  
Preferred Name English
DICALCIUM PHOSPHATE
INCI  
INCI  
Preferred Name English
ANHYDROUS DIBASIC CALCIUM PHOSPHATE
USP  
Common Name English
CALCIUM PHOSPHATE DIBASIC
WHO-DD  
Common Name English
CALCIUM PHOSPHATE (DIBASIC)
Common Name English
CALCIUM HYDROGEN PHOSPHATE ANHYDROUS
Common Name English
CALCIUM HYDROGEN ORTHOPHOSPHATE
Systematic Name English
INS-341(II)
Code English
CALCII HYDROGENOPHOSPHAS [WHO-IP LATIN]
Common Name English
CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS [II]
Common Name English
CALCIUM PHOSPHATE, DIBASIC
HSDB   MI  
Common Name English
CALCIUM PHOSPHATE,DIBASIC [VANDF]
Common Name English
CALCIUM PHOSPHATE, DIBASIC ANHYDROUS
Common Name English
PHOSPHORUS (AS DICALCIUM PHOSPHATE) [VANDF]
Common Name English
CALCIUM MONOHYDROGEN PHOSPHATE
Systematic Name English
PHOSPHORUS (AS CALCIUM PHOSPHATE,DIBASIC) [VANDF]
Common Name English
CALCIUM PHOSPHATE, DIBASIC [HSDB]
Common Name English
DICALCIUM ORTHOPHOSPHATE
Systematic Name English
PHOSPHORUS (AS DICALCIUM PHOSPHATE)
VANDF  
Common Name English
DIBASIC CALCIUM PHOSPHATE ANHYDROUS
Common Name English
Calcium phosphate dibasic [WHO-DD]
Common Name English
CALCIUM PHOSPHATE, DIBASIC [MI]
Common Name English
CALCIUM HYDROGEN MONOPHOSPHATE
Systematic Name English
ANHYDROUS DIBASIC CALCIUM PHOSPHATE [USP MONOGRAPH]
Common Name English
DIBASIC CALCIUM PHOSPHATE
Common Name English
CALCIUM (CALCIUM PHOSPHATE (DIBASIC))
Common Name English
CALCIUM HYDROGEN PHOSPHATE [EP MONOGRAPH]
Common Name English
CALCIUM (AS PHOSPHATE,DIBASIC) [VANDF]
Common Name English
INS NO.341(II)
Code English
CALCIUM HYDROGEN PHOSPHATE, ANHYDROUS [WHO-IP]
Common Name English
CALCIUM PHOSPHATE (1:1) [WHO-IP]
Common Name English
E-341(II)
Code English
ANHYDROUS DIBASIC CALCIUM PHOSPHATE [JAN]
Common Name English
CALCIUM HYDROGEN PHOSPHATE (ANHYDROUS)
Common Name English
PHOSPHORIC ACID, CALCIUM SALT (1:1)
Common Name English
CALCIUM HYDROGEN PHOSPHATE
Systematic Name English
SECONDARY CALCIUM PHOSPHATE
Common Name English
CALCIUM PHOSPHATE (1:1)
WHO-IP  
Systematic Name English
Classification Tree Code System Code
CODEX ALIMENTARIUS (GSFA) INS-341(II)
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
JECFA EVALUATION INS-341(II)
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
Code System Code Type Description
PUBCHEM
24441
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
RXCUI
47627
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
SMS_ID
100000087353
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
DAILYMED
L11K75P92J
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
WIKIPEDIA
DICALCIUM PHOSPHATE
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY Description: A white or almost white powder; odourless. Solubility: Practically insoluble in cold water and ethanol (~750 g/l) TS; soluble in dilute acids. Category: Tablet and capsule diluent. Storage: Calcium hydrogen phosphate should be kept in a well-closed container. Labelling: The designation on the container of Calcium hydrogen phosphate should state whether it is the dihydrate or the anhydrous form. Requirement: Calcium hydrogen phosphate contains not less than 30.9% and not more than the equivalent of 31.7% of calcium, Ca, calculated with reference to the ignited substance.
FDA UNII
L11K75P92J
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
DRUG BANK
DBSALT002430
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
CHEBI
32596
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
CHEBI
4496
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
NCI_THESAURUS
C77523
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
MERCK INDEX
m2964
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL2107567
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
ECHA (EC/EINECS)
231-826-1
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
HSDB
992
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
EPA CompTox
DTXSID20872529
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
CONCEPT Dietary Supplement
EVMPD
SUB16368MIG
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
RXCUI
253163
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
ALTERNATIVE
EVMPD
SUB11772MIG
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
CAS
7757-93-9
Created by admin on Mon Mar 31 17:59:40 GMT 2025 , Edited by admin on Mon Mar 31 17:59:40 GMT 2025
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
SOLVATE->ANHYDROUS
Related Record Type Details
ACTIVE MOIETY
ACTIVE MOIETY